Winston-Salem's ProKidney shared the results of its phase 2 study, marking a significant step forward as the cellular ...
Jules performs better than Gemini CLI despite using the same model, and more like Claude Code and OpenAI Codex.
22hon MSN
First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback